By understanding the diverse mechanisms of resistance including PSMA gene downregulation or compensatory activation of pathways (like androgen receptor reactivation) and developing targeted strategies, particularly by using combination therapies (integration of androgen receptor antagonists), it is hoped that long-term outcomes for patients with advanced PCa can be significantly improved. The gene discussed is AR; the disease is posterior cortical atrophy.